secwatch.observer — SEC 8-K summary
======================================

Issuer:     Relay Therapeutics, Inc. (RLAY)
CIK:        0001812364
Form:       8-K
Filed at:   2025-05-05T23:59:59+00:00
Accession:  0000950170-25-063539
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Relay Therapeutics Q1 net loss $77M; cash runway into 2029, RLY-2608 Phase 3 on track
--------------------------------------------------------------------------------

- Net loss $77.1M ($0.46/share) vs $81.4M ($0.62/share) in Q1 2024; revenue $7.7M from Elevar license completion.
- Cash $710.3M; runway extended into 2029, funding ReDiscover-2 past topline and vascular malformations proof-of-concept.
- Phase 3 ReDiscover-2 trial of RLY-2608+fulvestrant in breast cancer on track for mid-2025; ASCO abstract accepted.
- Initiated Phase 1 RLY-2608 vascular malformations trial in Q1 2025.
- Reduced workforce by ~70; research run rate cut ~80%; out-licensed RLY-4008 to Elevar with downstream economics.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1812364/000095017025063539/0000950170-25-063539-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1812364/000095017025063539/rlay-20250505.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-063539

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer